Twelve healthy volunteers were given one week's oral treatment with each of 300 mg nizatidine, 40 mg famotidine, and placebo once daily in a randomised, placebo controlled, double blind study. Three hours after administration, nizatidine led to a significant reduction in the mean (SD) resting heart rate compared with placebo (63.6 (6.4) beats/minute on placebo to 55.9 (7.2) beats/minute on nizatidine (p<005)), whereas famotidine did not influence the heart rate significantly. Both drugs, however, increased significantly the preejection period and the ratio of pre-ejection period to left ventricular ejection time on mechanocardiography and led to a significant decrease in cardiac output on impedance cardiography. The exercise heart rate on nizatidine as well as the resting heart rate on concurrent administration ofnizatidine and the P receptor blocking agent atenolol were subsequently investigated in the same volunteers. Nizatidine slightly inhibited exercise tachycardia by 4.4% (p<0.05). When compared with placebo, the mean resting heart rate was decreased on atenolol alone by a mean of 10.6 beats/minute (p<0.01) and fell further on coadministration with nizatidine to a total of 16.1 beats/minute (p<005 versus atenolol alone).
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Abstract Twelve healthy volunteers were given one week's oral treatment with each of 300 mg nizatidine, 40 mg famotidine, and placebo once daily in a randomised, placebo controlled, double blind study. Three hours after administration, nizatidine led to a significant reduction in the mean (SD) resting heart rate compared with placebo (63.6 (6.4) beats/minute on placebo to 55.9 (7.2) beats/minute on nizatidine (p<005)), whereas famotidine did not influence the heart rate significantly. Both drugs, however, increased significantly the preejection period and the ratio of pre-ejection period to left ventricular ejection time on mechanocardiography and led to a significant decrease in cardiac output on impedance cardiography. The exercise heart rate on nizatidine as well as the resting heart rate on concurrent administration ofnizatidine and the P receptor blocking agent atenolol were subsequently investigated in the same volunteers. Nizatidine slightly inhibited exercise tachycardia by 4.4% (p<0.05). When compared with placebo, the mean resting heart rate was decreased on atenolol alone by a mean of 10.6 beats/minute (p<0.01) and fell further on coadministration with nizatidine to a total of 16 .1 beats/minute (p<005 versus atenolol alone).
In conclusion, the effect of nizatidine in reducing the heart rate needs careful evaluation in elderly patients with heart failure or those also taking P3 blockers. In contrast to famotidine, long term treatment with 300 mg nizatidine a day has mainly negative chronotropic effects. Haemodynamic parameters were measured non-invasively using mechanocardiography (systolic time intervals) and impedance cardiography. Blood pressure (Riva-Rocci method) was also determined. Subjects were tested on the first and seventh treatment days before and at 90 minutes and three, six, and 12 hours after administration of the test substances, thereby permitting determination of haemodynamic effects after single and repeated dosing of these drugs.
The results of the preceding study prompted us to perform additional investigations. Firstly, the effects of nizatidine on non-invasively measured haemodynamic parameters were studied when combined with the P adrenergic blocking agent atenolol. This was a placebo controlled, randomised, double blind, cross over study wherein the same 12 healthy volunteers were each treated for one week periods with either placebo, 100 mg atenolol (plus one tablet placebo), or 300 mg nizatidine combined with 100 mg atenolol taken once daily; cross over was again separated by two week, wash out periods. All drugs were prepared as identically looking capsules. Impedance-and mechanocardiographic parameters were measured on the seventh treatment day before and at 90 minutes and three, six, and 12 hours after administration of the drugs.
Secondly, changes in heart rate after submaximal ergometric bicycle exercise were also determined. Testing of the same 12 subjects was carried out in a double blind fashion after treatment for one week on placebo and after one week on oral nizatidine 300 mg once daily. Exercise testing was performed three hours after dosing with subjects in the sitting position. Starting at 100 W, workload was increased in a stepwise manner every two minutes by 25 W until subjects achieved a heart rate of at least 165 beats/minute on placebo. Two weeks later, the same procedure and workload were used after nizatidine. Heart rate was measured by electrocardiogram. The test was performed at a room temperature ranging from 18°C to 22°C and at a relative humidity of 70%.
All subjects had given their written consent after a full explanation of the nature and purpose of the investigations. The study protocol was (Fig 1) . Famotidine significantly decreased the stroke volume, cardiac output, and the Heather index in impedance cardiography up to three hours after its administration (Table I) .
Mechanocardiography showed that both drugs significantly increased the pre-ejection period and PEP/LVET ratio up to three hours after administration (Table II) . As famotidine but not nizatidine resulted in raised PEPC value (heart rate corrected) three hours after intake, the effects of nizatidine on these parameters of cardiac performance were predominantly a result of its negative chronotropism. Neither famotidine nor nizatidine led to any clinically relevant TABLE II Mean (SD) pre-ejection period, heart rate corrected pre-ejection period, and the ratio ofthe pre-ejection period to the left ventricular ejection time before and 1 5, 3, 6, and 12 hours after one week's administration ofplacebo, 40 mgfamotidine, or 300 mg nizatidine PEP=pre-ejection period; PEP, =heart rate corrected pre-ejection period; PEP/LVET=ratio of the pre-ejection period to the left ventricular ejection time. Negative effects on cardiac performance have cle exercise by also been reported for famotidine, although these um heart rate, were not the result ofa reduction in heart rate.8 In :e hours after this study, both nizatidine and famotidine eats/minute on decreased cardiac output in impedance cardio-2).
graphy, thereby increasing both the pre-ejection period and the PEP/LVET ratio in mechanocardiography -effects that indicate negative [E AND influences on cardiac performance. The extent of these changes was more pronounced with famoti-[ministration of dine, clearly confirming previously reported ant fall in the data78 and indicating that it seems to exert direct murs after drug influences on myocardial contractility. By conluction in heart trast, nizatidine reduced cardiac output mainly 3.7 (6.4) beats/ because of its negative chronotropic properties, ter dosing when as a result ofwhich we would even have expected -of 10-6 beats/ to see an increase in stroke volume. Neverthete (p<0-01). A less, stroke volume on nizatidine remained art rate to 47.6 unchanged or even reduced indicating that this 1 when atenolol H, blocker may exert a slight negative inotropic p<O0O5 versus effect which was certainly less pronounced than ) indicating that that of famotidine.
the negative In conclusion, the results ofthis study could be his action ofthe of clinical importance, as the reductions in heart inutes and three rate after 300 mg of nizatidine were not just tration (Fig 3) , observed in single individuals but consistently found in all subjects investigated. Since these were noted in healthy subjects, the relevance of these findings to the treatment of elderly patients with heart failure and those who are also taking , blocker or verapamil therapy need careful evaluation. Finally, these results confirm previous data on the negative effects of famotidine on cardiac performance'7 8; effects which are not the result of the heart rate reducing properties of this H2 blocker.
